Last reviewed · How we verify

Pantoprazol — Competitive Intelligence Brief

Pantoprazol (Pantoprazol) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Gastroenterology.

marketed ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1 Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Pantoprazol (Pantoprazol) — Northern Orthopaedic Division, Denmark.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Pantoprazol TARGET Pantoprazol Northern Orthopaedic Division, Denmark marketed ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1
Protonix pantoprazole Generic (originally Byk Gulden/Altana/Nycomed) marketed Proton pump inhibitor (PPI) ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1 2000-02-02

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pantoprazol — Competitive Intelligence Brief. https://druglandscape.com/ci/pantoprazol. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: